Privately owned Oxford Nanopore offers a range of tools and and instruments based on a proprietary nanopore-based DNA and RNA sequencing technology.

The company presented Color Data as a resource for variant classification scientists and hopes it will inspire industry peers to similarly share data.

Count Me In is aiming to sign up more than 100,000 patients across all major cancer types, as well as rare cancers, over the next several years.

Researchers at Memorial Sloan Kettering Cancer Center identified clinically actionable germline mutations in 8.5 percent of about 2,700 unselected lung cancer patients.

The collaboration agreement includes support for development, regulatory submission, and commercialization of tests to guide use of Novartis' drug portfolio.

The five startup companies are focused on molecular diagnostics, precision oncology, personalized medicine, and more.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

DNA quantification and normalization are required in most genomics workflows, and are usually routinely implemented after the initial nucleic acid purification step. The versatility of the classical absorbance technique still makes it the go-to method for many applications, as the concentration of all DNA and RNA types can be determined using the specific empiric extinction coefficient for each nucleic acid type.

Quantitative PCR (qPCR) is a preferred method for quantification of low amounts of DNA or cDNA due to its high sensitivity, specificity and reproducibility. Consistently high and uniform qPCR efficiencies are crucial for accurate relative quantification of gene expression levels, low copy gene detection or absolute quantification of NGS libraries1.

Oct
03
Sponsored by
Illumina

Genomics is facilitating a deeper understanding of cancer biology and through clinical research, new biomarkers are emerging that pave the way for next-generation therapeutics to help fight cancer in a more personalized way.

In this webinar, Sandip Patel, MD will provide a review of biomarker research and discoveries in the field of Immunotherapy and Garret Hampton, PhD will discuss Illumina’s vision for Oncology and share how genomics will enable broader availability of comprehensive tumor sequencing to explore complex biomarkers and assess tumor mutational burden.